Nabla Bio Raises $26M in Series A Funding to Advance AI-Driven Drug Design
Nabla Bio is dedicated to transforming drug discovery with its advanced AI-driven platform.
Company Name: Nabla Bio
Location: Cambridge, MA
Sector: Biotechnology, AI Software
Funding Details: Raised $26M in Series A funding. The round was led by Radical Ventures, with participation from all existing investors, and included strategic collaborations with AstraZeneca, Bristol Myers Squibb Company, and Takeda.
Purpose of Investment: To expand operations and accelerate the development of atomically precise drug design technologies.
Leadership: Led by Surge Biswas and Frances Anastassacos.
Product: Nabla Bio develops integrated AI and wet-lab technologies that enable atomically precise drug design and high-throughput measurement of drug function. The company focuses initially on antibodies targeting multipass membrane proteins such as G protein-coupled receptors (GPCRs), ion channels, and transporters.
About Company: Nabla Bio is dedicated to transforming drug discovery with its advanced AI-driven platform. The company collaborates with leading pharmaceutical companies to expand drug pipelines with high-quality candidates against challenging targets. These partnerships not only enhance Nabla Bio’s R&D capabilities but also provide critical insights into disease biology, supporting the company’s rapid and sustainable growth.
